Abstract: Embodiments of the present disclosure provide a method for a base station, a method for a user device, a base station, and a user device. The method for the base station comprises: receiving a random access preamble from a user device through reception beamforming; and transmitting a random access response to the user device. The method for the user device comprises: transmitting a random access preamble to a base station; and receiving a random access response from the base station through reception beamforming. The embodiments of the present disclosure provide a random access channel procedure based on beamforming to combat strong path loss in a wireless communication environment (such as millimeter wave communication), so as to ensure uplink access of the user device effectively.

Abstract: Embodiments of the present disclosure relate to a method and a device for transmitting common control signals in a millimeter wave communication system. In one embodiment of the present disclosure, the method comprises: configuring a first beamforming codebook; precoding a plurality of common control signals respectively by using beamforming codewords in the first beamforming codebook, the plurality of common control signals being the same; sending, by using multiple beams, the plurality of precoded common control signals respectively to respective beam coverage regions in a cell in a space-division multiplexing manner. With embodiments of the present disclosure, beamformed transmission for synchronization/broadcasting/control signaling can fight against strong path loss in millimeter wave communication. Thereby, UEs accessing and precise update of system information later can be effectively guaranteed.

Abstract: Embodiments of the present invention provide an interference cancellation method for an enhanced physical downlink control channel E-PDCCH, comprising steps of: (1) allocating different orthogonal covering code OCC sequences to different cells and/or different users; and (2) combining a plurality of control channel elements CCEs constituting one PDCCH with a cell-specific OCC sequence and/or a user-specific OCC sequence respectively, so as to enable a user equipment to cancel interference on the PDCCH.

Abstract: The present disclosure relates to methods and devices for signal processing in a communication system. Embodiments of the present disclosure provide a method of signal transmission implemented in a base station, comprising: transmitting a narrow band signal on a part of a system bandwidth used by the base station; and while the narrow band signal is transmitted, setting at least a part of available bandwidth from the system bandwidth used by the base station unused for signal transmission. Embodiments of the present disclosure further provide a signal processing method implemented in a UE, comprising: receiving a narrow band signal transmitted on a part of a system bandwidth used by a base station, wherein, while the narrow band signal is transmitted by the base station, at least a part of an available bandwidth from a system bandwidth used by the base station is set unused for signal transmission.

Abstract: A substrate structure is provided, including: a carrier having at least a wiring area defined and positioned on a portion of a surface of the carrier; a first insulating layer formed on the wiring area; a wiring layer formed on the first insulating layer formed on the wiring area; and a second insulating layer formed on the wiring area. Therefore, a contact surface between the carrier and the first and second insulating layers is reduced by reducing the areas of the first and second insulating layers, whereby a substrate warpage due to mismatch of coefficients of thermal expansion (CTE) is avoided. The present invention further provides a method of manufacturing the substrate structure as described above.

Abstract: The present invention provides a semiconductor structure and a method of fabricating the same. The method includes: providing a chip having conductive pads, forming a metal layer on the conductive pads, forming a passivation layer on a portion of the metal layer, and forming conductive pillars on the metal layer. Since the metal layer is protected by the passivation layer, the undercut problem is solved, the supporting strength of the conductive pillars is increased, and the product reliability is improved.

Abstract: A pharmaceutical composition comprising sorafenib and GW5074. Said combination therapy inhibits cancer cell growth via c-Raf-PP2A-DAPK signaling transduction pathway in either in vitro or in preclinical animal model for orthotopic spontaneous kidney cancer which simulates clinical symptoms. Formation of the bond between c-Raf and GW5074 leads to conformational change which consequently increases the affinity between sorafenib and c-Raf. Binding with the specific drug target facilitates serine 308 dephosphorylation of DAPK by PP2A and induces necrosis in cancer cells. Serine 308 of DAPK protein may also be used as a biomarker for drug screening. This study provides a novel pharmaceutical composition comprising sorafenib and GW5074, a protein complex target consisting of c-Raf and DAPK for drug designing, as well as biomarkers including c-Raf protein, DAPK protein and phosphorylation status of DAPK for drug screening.

Abstract: The present invention provides a semiconductor structure and a method of fabricating the same. The method includes: providing a chip having conductive pads, forming a metal layer on the conductive pads, forming a passivation layer on a portion of the metal layer, and forming conductive pillars on the metal layer. Since the metal layer is protected by the passivation layer, the undercut problem is solved, the supporting strength of the conductive pillars is increased, and the product reliability is improved.

Abstract: The present invention provides a method, in a first node, for performing Co MP-based resource allocation for a second node, the method comprising steps of: a. selecting at least one Co MP hypothesis from among a plurality of Co MP hypo based on measurement theses based on measurement information reported by a second node; b. transmitting a resource allocation request to the second node; c. receiving feed-back information from the second node with response to the resource allocation request, and performing a corresponding operation. According to the method of the present embodiment, the CoMP transmission performance can be enhanced, and the second node has more freedom to select a CoMP hypothesis more suitable for the second node based on its own status.

Abstract: A substrate structure includes: a substrate body defined with a layout area, a sealing member and a cutting area, the sealing member being adjacent to the layout area, and the cutting area being adjacent to the sealing member; a wiring layer formed on the layout area; an insulating layer formed on the layout area and the wiring layer; and a metal layer formed on the insulating layer and the layout area. The insulating layer is prevented from being delaminated due to the formation of the metal layer.

Abstract: A pharmaceutical composition comprising sorafenib and GW5074. Said combination therapy inhibits cancer cell growth via c-Raf-PP2A-DAPK signaling transduction pathway in either in vitro or in preclinical animal model for orthotopic spontaneous kidney cancer which simulates clinical symptoms. Formation of the bond between c-Raf and GW5074 leads to conformational change which consequently increases the affinity between sorafenib and c-Raf. Binding with the specific drug target facilitates serine 308 dephosphorylation of DAPK by PP2A and induces necrosis in cancer cells. Serine 308 of DAPK protein may also be used as a biomarker for drug screening. This study provides a novel pharmaceutical composition comprising sorafenib and GW5074, a protein complex target consisting of c-Raf and DAPK for drug designing, as well as biomarkers including c-Raf protein, DAPK protein and phosphorylation status of DAPK for drug screening.

Abstract: The present invention relates to apparatuses and methods for exchange of signaling information in coordinated multi-point (CoMP). Partial embodiments of the present invention provide a method for exchange of signaling information in CoMP, where a first transmission point and a second transmission point provide CoMP for at least one user equipment (UE). The method includes: the first transmission point determining resource allocation for at least one of the first transmission point and the second transmission point, that is, the first transmission point notifying the second transmission point of the determined resource allocation. The resource allocation includes at least one of beamforming, power, and UE scheduling of the corresponding transmission point. The present invention can support CoMP under practical network conditions more effectively.

Abstract: A substrate structure is provided, which includes: a substrate body having a plurality of conductive pads; an insulating layer formed on the substrate body and having a plurality of openings for correspondingly exposing the conductive pads; and a plurality of ring bodies formed in the openings and corresponding in position to edges of the conductive pads. As such, a plurality of conductive elements can be subsequently formed inside the ring bodies so as to be prevented by the ring bodies from expanding outward during a reflow process, thereby protecting the insulating layer from being compressed by the conductive elements and preventing cracking of the insulating layer.

Abstract: A pharmaceutical composition comprising sorafenib and GW5074. Said combination therapy inhibits cancer cell growth via c-Raf-PP2A-DAPK signaling transduction pathway in either in vitro or in preclinical animal model for orthotopic spontaneous kidney cancer which simulates clinical symptoms. Formation of the bond between c-Raf and GW5074 leads to conformational change which consequently increases the affinity between sorafenib and c-Raf. Binding with the specific drug target facilitates serine 308 dephosphorylation of DAPK by PP2A and induces necrosis in cancer cells. Serine 308 of DAPK protein may also be used as a biomarker for drug screening. This study provides a novel pharmaceutical composition comprising sorafenib and GW5074, a protein complex target consisting of c-Raf and DAPK for drug designing, as well as biomarkers including c-Raf protein, DAPK protein and phosphorylation status of DAPK for drug screening.

Abstract: The present invention provides a semiconductor structure and a method of fabricating the same. The method includes: providing a chip having conductive pads, forming a metal layer on the conductive pads, forming a passivation layer on a portion of the metal layer, and forming conductive pillars on the metal layer. Since the metal layer is protected by the passivation layer, the undercut problem is solved, the supporting strength of the conductive pillars is increased, and the product reliability is improved.

Abstract: A substrate structure includes: a substrate body defined with a layout area, a sealing member and a cutting area, the sealing member being adjacent to the layout area, and the cutting area being adjacent to the sealing member; a wiring layer formed on the layout area; an insulating layer formed on the layout area and the wiring layer; and a metal layer formed on the insulating layer and the layout area. The insulating layer is prevented from being delaminated due to the formation of the metal layer.

Abstract: A substrate structure is provided, including: a carrier having at least a wiring area defined and positioned on a portion of a surface of the carrier; a first insulating layer formed on the wiring area; a wiring layer formed on the first insulating layer formed on the wiring area; and a second insulating layer formed on the wiring area. Therefore, a contact surface between the carrier and the first and second insulating layers is reduced by reducing the areas of the first and second insulating layers, whereby a substrate warpage due to mismatch of coefficients of thermal expansion (CTE) is avoided. The present invention further provides a method of manufacturing the substrate structure as described above.

Abstract: The invention relates to a method, in a first base station (110) of a wireless communication network, of calibrating an offset of an antenna array of the first base station relative to an antenna array of a second base station (120) in the wireless communication network, the method including the steps of: dividing a whole parameter offset range into a plurality of segments (S211) according to the requirement of calibration precision and assigning a feature value for each segment; compensating uplink channel state information according to the feature value assigned to one of the plurality of segments in a predetermined order in a first cycle (S411); designing a pre-coding vector or matrix for downlink data transmission according to a compensation result (S413), pre-coding downlink data and subsequently transmitting the downlink data to a user equipment cooperatively with the second base station (S414, S423); and judging whether all the segments of the parameter offset range have been traversed (S415), and if a

Abstract: A substrate structure is provided, which includes: a substrate body having a plurality of conductive pads; an insulating layer formed on the substrate body and having a plurality of openings for correspondingly exposing the conductive pads; and a plurality of ring bodies formed in the openings and corresponding in position to edges of the conductive pads. As such, a plurality of conductive elements can be subsequently formed inside the ring bodies so as to be prevented by the ring bodies from expanding outward during a reflow process, thereby protecting the insulating layer from being compressed by the conductive elements and preventing cracking of the insulating layer.

Abstract: A pharmaceutical composition comprising sorafenib and GW5074. Said combination therapy inhibits cancer cell growth via c-Raf-PP2A-DAPK signaling transduction pathway in either in vitro or in preclinical animal model for orthotopic spontaneous kidney cancer which simulates clinical symptoms. Formation of the bond between c-Raf and GW5074 leads to conformational change which consequently increases the affinity between sorafenib and c-Raf. Binding with the specific drug target facilitates serine 308 dephosphorylation of DAPK by PP2A and induces necrosis in cancer cells. Serine 308 of DAPK protein may also be used as a biomarker for drug screening. This study provides a novel pharmaceutical composition comprising sorafenib and GW5074, a protein complex target consisting of c-Raf and DAPK for drug designing, as well as biomarkers including c-Raf protein, DAPK protein and phosphorylation status of DAPK for drug screening.